Health & Fitness
Health and Fitness
Health and Fitness 
Tue, February 8, 2011
Mon, February 7, 2011
Unigene to Present at the 13th Annual BIO CEO and Investor Conference on February 14, 2011
BOONTON, N.J.--([ BUSINESS WIRE ])--Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that Ashleigh Palmer, President and CEO will be presenting a corporate overview at the 13th Annual BIO CEO & Investor Conference. Mr. Palmera™s presentation is scheduled to begin at 9:30 a.m. Eastern time on Monday, February 14, 2011.
Individuals can listen to a live webcast of the presentation by logging on to the Investors and Media section of the Unigene web site, [ http://www.unigene.com ]. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's web site for 30 days.
About Unigene Laboratories, Inc.
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligencea" platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.
Unigenea™s technologies have extensive clinical and partner validation. The Companya™s first product to market, Fortical®, a nasal calcitonin product, received FDA approval in 2005 and is marketed in the U.S. by Upsher-Smith for the treatment of postmenopausal osteoporosis. Pivotal clinical programs include an oral calcitonin licensed to Tarsa Therapeutics, now in Phase 3 testing for the treatment of osteoporosis. Other validating relationships include an oral parathyroid hormone entering Phase 2 in the first quarter of 2011 and licensed to GlaxoSmithKline. In addition, Unigene has a manufacturing license agreement with Novartis, which is completing three Phase 3 studies of oral calcitonin for the treatment of osteoporosis and osteoarthritis.
For more information about Unigene, please visit [ http://www.unigene.com ]. For information about Fortical, please visit [ http://www.fortical.com ].